口服超长效药物递送:面向疟疾消除目标的应用
研究开发了一种口服超长效胶囊,在胃内溶出后展开为星形剂型,滞留胃内数天至数周并持续释放小分子药物,溶蚀后组件可安全通过胃肠道。在猪模型中未观察到胃肠道梗阻或黏膜损伤,伊维菌素剂型可维持治疗剂量释放长达14天,数学模型显示该系统可增强大规模给药对疟疾消除的效果。
要点
- 口服超长效胶囊在胃内展开为星形剂型,滞留胃内并持续释放药物数天至数周。
- 猪模型临床、影像和内镜评估未见胃肠道梗阻或黏膜损伤。
- 伊维菌素胃滞留剂型在猪模型中维持治疗剂量释放长达14天。
核心结论
- 封装式胃滞留超长效递送剂型有望革新疟疾及其他需依从性才能奏效的大人群疾病的治疗选择。
研究设计与样本
- 开发口服超长效胶囊,在胃内溶出后展开为星形剂型以延长胃滞留并释放药物。
- 在猪大动物模型中给予该剂型,进行临床、影像学和内镜评估。
- 制备伊维菌素胃内控释长效制剂并整合入该剂型,在猪模型中评估释放。
- 采用纳入伊维菌素对疟疾传播蚊致死效应的疟疾传播数学模型进行评估。
主要发现
- 该胃滞留剂型可释放小分子药物数天至数周,并可能更长。
- 猪模型临床、影像学和内镜评估未显示胃肠道梗阻或黏膜损伤的证据。
- 伊维菌素剂型在猪模型中持续释放治疗剂量长达14天。
- 数学模型显示该系统可增强大规模给药对疟疾消除目标的效力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Efforts at elimination of scourges, such as malaria, are limited by the logistic challenges of reaching large rural populations and ensuring patient adherence to adequate pharmacologic treatment. We have developed an oral, ultra-long-acting capsule that dissolves in the stomach and deploys a star-shaped dosage form that releases drug while assuming a geometry that prevents passage through the pylorus yet allows passage of food, enabling prolonged gastric residence. This gastric-resident, drug delivery dosage form releases small-molecule drugs for days to weeks and potentially longer. Upon dissolution of the macrostructure, the components can safely pass through the gastrointestinal tract. Clinical, radiographic, and endoscopic evaluation of a swine large-animal model that received these dosage forms showed no evidence of gastrointestinal obstruction or mucosal injury. We generated long-acting formulations for controlled release of ivermectin, a drug that targets malaria-transmitting mosquitoes, in the gastric environment and incorporated these into our dosage form, which then delivered a sustained therapeutic dose of ivermectin for up to 14 days in our swine model. Further, by using mathematical models of malaria transmission that incorporate the lethal effect of ivermectin against malaria-transmitting mosquitoes, we demonstrated that this system will boost the efficacy of mass drug administration toward malaria elimination goals. Encapsulated, gastric-resident dosage forms for ultra-long-acting drug delivery have the potential to revolutionize treatment options for malaria and other diseases that affect large populations around the globe for which treatment adherence is essential for efficacy.
引用
- Bellinger AM, Jafari M, Grant TM, et al. Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals. Sci Transl Med. 2016. PMID: 27856796
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。